Loading...

Register by
March 12, 2010
and SAVE up to $350!

Loading...

Join our LinkedIn Group
and stay connected!

Corporate Sponsors

AppliedBiosystems

Attana

Caprotec

Elsevier

EMD Novagen(1)

GE Healthcare

Sponsoring Organization

dsec small logo


Lead Sponsoring Publications

American Pharmaceutical Review - APR

Bio-IT-Word_logo

GEN_logo

International_drug_disc

Nature_logo

Science AAAS logo

The Scientist

Additional Media Partners

Loading...

IMG Web Header


Day 1  |  Day 2 |  Download Brochure 

Recommended Short Courses*

Monday, June 14
9:00 am – 12:00 pm
(SC1) Reactive Metabolites in Drug Discovery and Development-A Critical Examination of the Issues

2:00 pm – 5:00 pm
(SC5) Dealing with the Blood-Brain Barrier


 

WEDNESDAY, JUNE 16

 

12:30 pm Registration


KEYNOTE SESSION
in vivo Imaging—Where is it Having
the Biggest Impact in Drug Development?

1:55 Chairperson's Opening Remarks

Susanta Sarkar, Ph.D., Director, Clinical Imaging, Medicines Development, Oncology R&D, GlaxoSmithKline

2:00 Molecular Imaging Approaches: How can it Help Drug Discovery and Development?

Susanta Sarkar, Ph.D., Director, Clinical Imaging, Medicines Development, Oncology R&D, GlaxoSmithKline

It is critical to develop technologies that reduce attrition rates to improve the efficiency of the overall drug development process. This talk will discuss how the successful integration of molecular imaging approaches from bench to bedside would not only streamline drug development process but also allow for new opportunities in treatment management of targeted therapies including patient selection, dose optimization and optimal drug regimen.

2:30 Platform Imaging Biomakers—Applications across Pre-Clinical Drug Discovery with a Focus on Neuroscience, Oncology, Cardiovascular and Future Horizons

Thomas BocanThomas Bocan, Ph.D., Senior Director & Head, BioImaging Center, Pfizer Global Research & Development, Pfizer, Inc.

Imaging biomarkers allow for the pre-clinical and clinical assessment of proof of mechanism of novel drug candidates. With the development of novel PET tracers, imaging reagents and MR approaches, opportunities exist to broaden application to evolving tissue regeneration and stem cell approaches. Application of platform tools across numerous pharmacologic approaches such as AMPA potentiators, potassium channel openers, antiproliferatives and Alzheimer’s progression will be discussed.


3:00 Sponsored Presentations:The Data Deluge – An Acute Informatics Problem (Opportunity Available)

3:30 Networking Refreshment Break, Poster and Exhibit Viewing

4:30 Role for in vivo Imaging in the Development of Companion Diagnostics & Advancement of Drug Discovery

Francis Kalush, Ph.D., Network Leader, Diagnostics, Office of the Center Director, Center for Devices and Radiological Health, FDA

5:00 Novel PET Tracers as Translational Tools in Drug Discovery and Development

Dennis McCarthyDennis McCarthy, Ph.D., Director, Early Development, AstraZeneca R&D

Drug development is a time-consuming and costly endeavor. We now benefit from the discovery of new PET tracers that can be used to streamline this process. Their development requires a multidisciplinary approach combining the expertise of many fields. I will describe the discovery of new PET tracers and how, as translational tools, they can be used to expand our understanding of receptor biology and disease.


5:30 End of Day


Day 1  |  Day 2  |  Download Brochure

Loading...




Brochure Download

Short Courses Brochure Download